Left ventricular hypertrophy detection and body mass index in essential hypertension

被引:11
作者
Cuspidi, Cesare [1 ,2 ]
Giudici, Valentina [2 ]
Lonati, Laura [2 ]
Sala, Carla [3 ,4 ]
Valerio, Cristiana [2 ]
Mancia, Giuseppe [1 ,2 ,4 ]
机构
[1] Univ Milano Bicocca, Dept Clin Med & Prevent, Milan, Italy
[2] Ist Auxol Italiano, Milan, Italy
[3] Univ Milan, Thoracopulm & Cardiocirculatory Dept, Fdn Osped Maggiore Policlin, Milan, Italy
[4] Univ Milan, Ctr Interuniv Fisiol Clin & Ipertens, Milan, Italy
关键词
Body size; indexation methods; left ventricular hypertrophy; OF-ECHOCARDIOGRAPHYS GUIDELINES; END-POINT REDUCTION; CARDIOVASCULAR RISK; LOSARTAN INTERVENTION; STANDARDS COMMITTEE; EUROPEAN-SOCIETY; BLOOD-PRESSURE; ORGAN DAMAGE; TASK-FORCE; RECOMMENDATIONS;
D O I
10.3109/08037051.2010.506029
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Background and aim. Weight and height are two major determinants of left ventricular mass (LVM); the anthropometric parameter to which LVM should be normalized remains, however, debated. In a population of hypertensives, we compared the prevalence of left ventricular hypertrophy (LVH) defined by two indexation criteria of LVM in different subgroups of body mass index (BMI). Methods. A total of 4468 essential hypertensives included in the E valuation of Target Organ Damage in Hypertension (ETODH), were divided in four groups according to BMI thresholds: lean (BMI<20 kg/m(2), 4.5%), normal (20-24.9 kg/m(2), 36.5%), overweight (25-29.9 kg/m(2), 41.9%) and obese (>= 30 kg/m(2), 17.1%). All patients underwent quantitative echocardiography; LVH was defined by two criteria of LVM indexation: (A) >= 116 g/m(2) in men and >= 96 g/m(2) in women; (B) >= 49 g/m(2.7) in men and >= 45 g/m(2.7) in women. Results. Overall, 44.9% of the patients were found to have LVH by criterion A, 48.2% by criterion B and 37.0% by both criteria. Prevalence rates of LVH in the four BMI groups were 34.3%, 40.5%, 47.3%, 53.9% by criterion A, 19.8%, 37.0%, 53.6%, 69.7% by criterion B, and 14.2%, 30.9%, 41.5%, 47.8% by both criteria, respectively (p at least <0.05 for all). Conclusions. Our findings show that LVH prevalence in both overweight and obese hypertensives is higher when LVM is normalized to height(2.7) compared with body surface area (BSA), whereas the opposite trend occurs in normal weight/lean hypertensives. Thus, the risk related to LVH is underestimated when the LVH/height(2.7) criterion is applied to lean/normal weight individuals and the LVH/BSA criterion in overweight/obese individuals.
引用
收藏
页码:337 / 343
页数:7
相关论文
共 27 条
[1]   Left ventricular hypertrophy increases cardiovascular risk independently of in-office and out-of-office blood pressure values [J].
Bombelli, Michele ;
Facchetti, Rita ;
Carugo, Stefano ;
Madotto, Fabiana ;
Arenare, Francesca ;
Quarti-Trevano, Fosca ;
Capra, Anna ;
Giannattasio, Cristina ;
Dell'Oro, Raffaella ;
Grassi, Guido ;
Sega, Roberto ;
Mancia, Giuseppe .
JOURNAL OF HYPERTENSION, 2009, 27 (12) :2458-2464
[2]   Left ventricular hypertrophy as a predictor of coronary heart disease mortality and the effect of hypertension [J].
Brown, DW ;
Giles, WH ;
Croft, JB .
AMERICAN HEART JOURNAL, 2000, 140 (06) :848-856
[3]   Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure [J].
Chobanian, AV ;
Bakris, GL ;
Black, HR ;
Cushman, WC ;
Green, LA ;
Izzo, JL ;
Jones, DW ;
Materson, BJ ;
Oparil, S ;
Wright, JT ;
Roccella, EJ .
HYPERTENSION, 2003, 42 (06) :1206-1252
[4]   Indexation of left ventricular mass to body surface area and height to allometric power of 2.7: is the difference limited to obese hypertensives? [J].
Cuspidi, C. ;
Meani, S. ;
Negri, F. ;
Giudici, V. ;
Valerio, C. ;
Sala, C. ;
Zanchetti, A. ;
Mancia, G. .
JOURNAL OF HUMAN HYPERTENSION, 2009, 23 (11) :728-734
[5]  
Cuspidi C, 2009, J HYPERTENS, V27, pS156
[6]   Prevalence of left ventricular hypertrophy and carotid thickening in a large selected hypertensive population: Impact of different echocardiographic and ultrasonographic diagnostic criteria [J].
Cuspidi, C ;
Lonati, L ;
Macca, G ;
Sampieri, L ;
Fusi, V ;
Michev, I ;
Severgnini, B ;
Salerno, M ;
Magrini, F ;
Zanchetti, A .
BLOOD PRESSURE, 2001, 10 (03) :142-149
[7]   Cardio-renal organ damage and cardiovascular outcomes in hypertension [J].
Cuspidi, Cesare .
JOURNAL OF HYPERTENSION, 2009, 27 (04) :702-706
[8]   Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy -: The LIFE (losartan intervention for endpoint reduction in hypertension) study [J].
de Simone, G ;
Wachtell, K ;
Palmieri, V ;
Hille, DA ;
Beevers, G ;
Dahlöf, B ;
de Faire, U ;
Fyhrquist, F ;
Ibsen, H ;
Julius, S ;
Kjeldsen, SE ;
Lederballe-Pedersen, O ;
Lindholm, LH ;
Nieminen, MS ;
Omvik, P ;
Oparil, S ;
Devereux, RB .
CIRCULATION, 2005, 111 (15) :1924-1931
[9]   Normalization for body size and population-attributable risk of left ventricular hypertrophy - The strong heart study [J].
de Simone, G ;
Kizer, JR ;
Chinali, M ;
Roman, MJ ;
Bella, JN ;
Best, LG ;
Lee, ET ;
Devereux, RB .
AMERICAN JOURNAL OF HYPERTENSION, 2005, 18 (02) :191-196
[10]   Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol -: The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial [J].
Devereux, RB ;
Dahlöf, B ;
Gerdts, E ;
Boman, K ;
Nieminen, MS ;
Papademetriou, V ;
Rokkedal, J ;
Harris, KE ;
Edelman, JM ;
Wachtell, K .
CIRCULATION, 2004, 110 (11) :1456-1462